Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ASTH vs UNH vs CVS vs ALHC vs OSCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
ASTH vs UNH vs CVS vs ALHC vs OSCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $2.01B | $335.60B | $111.40B | $3.73B | $5.41B |
| Revenue (TTM) | $3.53B | $449.71B | $407.90B | $4.26B | $13.30B |
| Net Income (TTM) | $30M | $12.04B | $2.93B | $20M | $-39M |
| Gross Margin | 6.8% | 18.8% | 13.9% | 9.0% | 17.4% |
| Operating Margin | 2.5% | 4.2% | 1.5% | 0.8% | 0.1% |
| Forward P/E | 29.1x | 20.2x | 12.2x | 140.9x | 34.7x |
| Total Debt | $1.08B | $78.39B | $93.59B | $338M | $430M |
| Cash & Equiv. | $429M | $24.36B | $8.51B | $578M | $2.77B |
ASTH vs UNH vs CVS vs ALHC vs OSCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Astrana Health, Inc. (ASTH) | 100 | 133.2 | +33.2% |
| UnitedHealth Group … (UNH) | 100 | 99.4 | -0.6% |
| CVS Health Corporat… (CVS) | 100 | 116.1 | +16.1% |
| Alignment Healthcar… (ALHC) | 100 | 83.2 | -16.8% |
| Oscar Health, Inc. (OSCR) | 100 | 77.6 | -22.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASTH vs UNH vs CVS vs ALHC vs OSCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ASTH ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 56.4%, EPS growth -48.9%, 3Y rev CAGR 40.6%
- 6.1% 10Y total return vs UNH's 220.6%
- 56.4% revenue growth vs CVS's 7.8%
UNH carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 25 yrs, beta 0.59, yield 2.4%
- 2.7% margin vs OSCR's -0.3%
- 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (2 stocks pay no dividend)
- 3.9% ROA vs OSCR's -0.6%
CVS is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.05, current ratio 0.84x
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 140.9x)
- Beta 0.05 vs OSCR's 1.84
ALHC lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, OSCR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 56.4% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (12.2x vs 140.9x) | |
| Quality / Margins | 2.7% margin vs OSCR's -0.3% | |
| Stability / Safety | Beta 0.05 vs OSCR's 1.84 | |
| Dividends | 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +34.7% vs UNH's -3.2% | |
| Efficiency (ROA) | 3.9% ROA vs OSCR's -0.6% |
ASTH vs UNH vs CVS vs ALHC vs OSCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ASTH vs UNH vs CVS vs ALHC vs OSCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UNH leads in 2 of 6 categories
CVS leads 1 • ASTH leads 0 • ALHC leads 0 • OSCR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 127.5x ASTH's $3.5B. Profitability is closely matched — net margins range from 2.7% (UNH) to -0.3% (OSCR). On growth, ASTH holds the edge at +55.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.5B | $449.7B | $407.9B | $4.3B | $13.3B |
| EBITDAEarnings before interest/tax | $141M | $23.2B | $10.5B | $66M | $40M |
| Net IncomeAfter-tax profit | $30M | $12.0B | $2.9B | $20M | -$39M |
| Free Cash FlowCash after capex | $158M | $19.7B | $7.4B | $237M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +6.8% | +18.8% | +13.9% | +9.0% | +17.4% |
| Operating MarginEBIT ÷ Revenue | +2.5% | +4.2% | +1.5% | +0.8% | +0.1% |
| Net MarginNet income ÷ Revenue | +0.9% | +2.7% | +0.7% | +0.5% | -0.3% |
| FCF MarginFCF ÷ Revenue | +4.5% | +4.4% | +1.8% | +5.6% | +21.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +55.6% | +2.0% | +6.2% | +33.3% | +52.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +107.1% | +0.7% | +63.1% | +2.1% | +125.0% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 27.9x trailing earnings, UNH trades at a 64% valuation discount to ASTH's 78.4x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than ALHC's 77.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.0B | $335.6B | $111.4B | $3.7B | $5.4B |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $389.6B | $196.5B | $3.5B | $3.1B |
| Trailing P/EPrice ÷ TTM EPS | 78.43x | 27.95x | 62.81x | -4932.43x | -12.35x |
| Forward P/EPrice ÷ next-FY EPS est. | 29.12x | 20.19x | 12.19x | 140.93x | 34.65x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 21.39x | 16.70x | 13.11x | 77.12x | — |
| Price / SalesMarket cap ÷ Revenue | 0.63x | 0.75x | 0.28x | 0.94x | 0.46x |
| Price / BookPrice ÷ Book value/share | 3.19x | 3.31x | 1.47x | 20.16x | 5.58x |
| Price / FCFMarket cap ÷ FCF | 19.24x | 20.88x | 14.27x | 32.95x | 5.11x |
Profitability & Efficiency
UNH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-3 for OSCR. OSCR carries lower financial leverage with a 0.44x debt-to-equity ratio, signaling a more conservative balance sheet compared to ASTH's 1.93x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs ASTH's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.9% | +11.5% | +3.9% | +11.5% | -3.3% |
| ROA (TTM)Return on assets | +1.5% | +3.9% | +1.1% | +1.8% | -0.6% |
| ROICReturn on invested capital | +6.2% | +9.2% | +5.0% | — | — |
| ROCEReturn on capital employed | +6.1% | +9.7% | +6.1% | +2.9% | -25.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | 1.93x | 0.77x | 1.24x | 1.89x | 0.44x |
| Net DebtTotal debt minus cash | $649M | $54.0B | $85.1B | -$240M | -$2.3B |
| Cash & Equiv.Liquid assets | $429M | $24.4B | $8.5B | $578M | $2.8B |
| Total DebtShort + long-term debt | $1.1B | $78.4B | $93.6B | $338M | $430M |
| Interest CoverageEBIT ÷ Interest expense | 2.49x | 4.71x | 2.11x | 1.27x | -0.57x |
Total Returns (Dividends Reinvested)
Evenly matched — ASTH and CVS and OSCR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $7,726 for ALHC. Over the past 12 months, CVS leads with a +34.7% total return vs UNH's -3.2%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +43.1% | +10.6% | +10.6% | -9.7% | +39.4% |
| 1-Year ReturnPast 12 months | +12.3% | -3.2% | +34.7% | +17.6% | +22.6% |
| 3-Year ReturnCumulative with dividends | +3.1% | -19.9% | +36.6% | +152.4% | +177.5% |
| 5-Year ReturnCumulative with dividends | +7.8% | -2.6% | +17.0% | -22.7% | -7.3% |
| 10-Year ReturnCumulative with dividends | +614.5% | +220.6% | +3.5% | +5.4% | -40.0% |
| CAGR (3Y)Annualised 3-year return | +1.0% | -7.1% | +11.0% | +36.2% | +40.5% |
Risk & Volatility
Evenly matched — ASTH and CVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASTH currently trades 99.7% from its 52-week high vs ALHC's 76.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 0.59x | 0.05x | 0.75x | 1.84x |
| 52-Week HighHighest price in past year | $36.20 | $395.52 | $88.63 | $23.87 | $23.80 |
| 52-Week LowLowest price in past year | $18.08 | $234.60 | $58.35 | $11.63 | $10.69 |
| % of 52W HighCurrent price vs 52-week peak | +99.7% | +93.5% | +98.5% | +76.5% | +87.7% |
| RSI (14)Momentum oscillator 0–100 | 76.8 | 75.9 | 69.3 | 37.3 | 78.5 |
| Avg Volume (50D)Average daily shares traded | 478K | 7.9M | 7.4M | 3.6M | 6.5M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ASTH as "Buy", UNH as "Buy", CVS as "Buy", ALHC as "Buy", OSCR as "Hold". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs -19.7% for OSCR (target: $17). For income investors, CVS offers the higher dividend yield at 3.06% vs ASTH's 0.44%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $34.20 | $385.43 | $95.20 | $24.83 | $16.75 |
| # AnalystsCovering analysts | 9 | 52 | 41 | 16 | 11 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | +2.4% | +3.1% | — | — |
| Dividend StreakConsecutive years of raises | 1 | 25 | 0 | — | — |
| Dividend / ShareAnnual DPS | $0.16 | $8.70 | $2.67 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.8% | +1.7% | 0.0% | 0.0% | 0.0% |
UNH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 1 (Valuation Metrics). 3 tied.
ASTH vs UNH vs CVS vs ALHC vs OSCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ASTH or UNH or CVS or ALHC or OSCR a better buy right now?
For growth investors, Astrana Health, Inc.
(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 9x trailing P/E (20. 2x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ASTH or UNH or CVS or ALHC or OSCR?
On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.
9x versus Astrana Health, Inc. at 78. 4x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ASTH or UNH or CVS or ALHC or OSCR?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -22. 7% for Alignment Healthcare, Inc. (ALHC). Over 10 years, the gap is even starker: ASTH returned +614. 5% versus OSCR's -40. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ASTH or UNH or CVS or ALHC or OSCR?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 3531% more volatile than CVS relative to the S&P 500. On balance sheet safety, Oscar Health, Inc. (OSCR) carries a lower debt/equity ratio of 44% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ASTH or UNH or CVS or ALHC or OSCR?
By revenue growth (latest reported year), Astrana Health, Inc.
(ASTH) is pulling ahead at 56. 4% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ASTH or UNH or CVS or ALHC or OSCR?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus -3. 8% for Oscar Health, Inc. — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -3. 4% for OSCR. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ASTH or UNH or CVS or ALHC or OSCR more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 128. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.
08Which pays a better dividend — ASTH or UNH or CVS or ALHC or OSCR?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), ASTH (0. 4% yield) pay a dividend. ALHC, OSCR do not pay a meaningful dividend and should not be held primarily for income.
09Is ASTH or UNH or CVS or ALHC or OSCR better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ASTH and UNH and CVS and ALHC and OSCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ASTH is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; ALHC is a small-cap high-growth stock; OSCR is a small-cap high-growth stock. UNH, CVS pay a dividend while ASTH, ALHC, OSCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.